PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29197565-4	2018	Lately, two metabolites that are markedly increased in NP-C patients are arising as biomarkers for this disease screening: 7-ketocholesterol and cholestane-3beta,5alpha,6beta-triol, both oxidized cholesterol products.	7-ketocholesterol	123-140	NPC intracellular cholesterol transporter 1	Homo sapiens	55-59	
27256227-1	2016	OBJECTIVE: To investigate 7-ketocholesterol (7-KC) level in the blood, clinical features and gene mutation of Niemann-Pick disease type C (NPC).	7-ketocholesterol	26-43	NPC intracellular cholesterol transporter 1	Homo sapiens	110-137	
27256227-1	2016	OBJECTIVE: To investigate 7-ketocholesterol (7-KC) level in the blood, clinical features and gene mutation of Niemann-Pick disease type C (NPC).	7-ketocholesterol	26-43	NPC intracellular cholesterol transporter 1	Homo sapiens	139-142	
26733147-4	2016	As expected, NP-C patients showed significant increase of both C-triol and 7-KC.	7-ketocholesterol	75-79	NPC intracellular cholesterol transporter 1	Homo sapiens	13-17	
26239048-2	2015	Recent studies have shown that plasma cholestane-3beta,5alpha,6beta-triol (CT) and 7-ketocholesterol (7-KC) could be potential biomarkers for the diagnosis of NPC patients.	7-ketocholesterol	83-100	NPC intracellular cholesterol transporter 1	Homo sapiens	159-162	
21518695-3	2011	Recently, we demonstrated that two cholesterol oxidation products, specifically cholestane-3beta,5alpha,6beta-triol (3beta,5alpha,6beta-triol) and 7-ketocholesterol (7-KC), were markedly increased in the plasma of human NPC1 subjects, suggesting a role for these oxysterols in diagnosis of NPC1 disease and evaluation of therapeutics in clinical trials.	7-ketocholesterol	147-164	NPC intracellular cholesterol transporter 1	Homo sapiens	220-224	
10751394-10	2000	Finally, we showed that the lysosomal cholesterol pool in NP-C cells was substantially and preferentially reduced by incubating cells with the oxysterols, 25-hydroxycholesterol and 7-ketocholesterol; these findings suggest a new pharmacological approach to the treatment of NP-C disease.	7-ketocholesterol	181-198	NPC intracellular cholesterol transporter 1	Homo sapiens	58-62	
34177581-7	2021	Plasma 7-ketocholesterol (7-KC), an emerging biomarker of NP-C1, was the primary endpoint.	7-ketocholesterol	7-24	NPC intracellular cholesterol transporter 1	Homo sapiens	58-63